NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026